Poxel - Pharmaceutical Company set-up to find innovative solutions for metabolic diseases management with a primary focus on type 2 diabetes


Three major investment firms took part in a €16 million Series A financing round in July 2010, the largest in France since 2005.


Edmond de Rotschild investment partners


CDC entreprises


Crédit Agricole Private Equity

The financing round was led by Edmond de Rothschild Investment Partners (EdRIP) and also included InnoBio Fund, managed by CDC Enterprises within the FSI France Investment program, and Crédit Agricole Private Equity (CAPE). Neither Merck KGaA nor Merck Serono is a shareholder of Poxel.

Paris-based Edmond de Rothschild Investment Partners (www.edrip.fr) is dedicated to minority investments in privately-owned companies. It currently has €800 million under management, which is being invested primarily as life sciences venture capital and growth capital.

InnoBio is a French venture capital fund of €140 million, managed by CDC Enterprises (www.cdcentreprises.fr) and for 37 per cent

subscribed by the FSI and leading international pharmaceutical companies in France. The fund makes direct equity and quasi-equity investments in companies that provide innovative technological products and services in the healthcare market.

Crédit Agricole Private Equity (www.ca-privateequity.com) is an AMF-accredited asset- management subsidiary of Crédit Agricole S.A., specializing in direct private- equity investment in non-listed companies. Its team operates in a variety of areas and manages €2.8 billion. The venture capital team manages €400 million through FCPIs invested in young companies with high growth potential in the technology and life sciences sectors.

Sitemap | Legal
© Poxel SA